Autophagy deficiency in β cells blunts incretininduced suppression of glucagon release from α cells

Islets

Volumn 7, Issue 5, 2015, Pages

  Kim, Min Joo ^a,b   Choi, Ok Kyong ^c   Chae, Kyung Sil ^c   Lee, Hakmo ^c   Chung, Sung Soo ^c   Ham, Dong Sik ^d   Kim, Ji Won ^d   Yoon, Kun Ho ^d   Park, Kyong Soo ^a,c   Jung, Hye Seung ^a,c  

^a Seoul National University College of Medicine   (South Korea)

^b Korea Cancer Center Hospital   (South Korea)

^c Cell and Gene Therapy Res Institute   (South Korea)

^d The Catholic University of Korea   (South Korea)

Author keywords

A cell; Autophagy; Dipeptidyl peptidase IV inhibitors; Glucagon; Incretins; Vildagliptin

Indexed keywords

CYCLIC AMP; EXENDIN 4; INCRETIN; MESSENGER RNA; VILDAGLIPTIN; GLUCAGON;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; AUTOPHAGY; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; GLUCAGON RELEASE; GLUCOSE TOLERANCE TEST; HYPOINSULINEMIA; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; INSULIN RELEASE; INSULIN TOLERANCE TEST; MALE; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PANCREAS ISLET ALPHA CELL; PANCREAS ISLET BETA CELL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; ANIMAL; DRUG EFFECTS; EXPERIMENTAL DIABETES MELLITUS; GLUCOSE INTOLERANCE; METABOLISM; PANCREAS ISLET; PATHOLOGY;

ANIMALS; AUTOPHAGY; DIABETES MELLITUS, EXPERIMENTAL; GLUCAGON; GLUCAGON-SECRETING CELLS; GLUCOSE INTOLERANCE; INCRETINS; INSULIN-SECRETING CELLS; ISLETS OF LANGERHANS; MALE; MICE;

EID: 84964067902     PISSN: 19382014     EISSN: 19382022     Source Type: Journal    
DOI: 10.1080/19382014.2015.1129096     Document Type: Article

References (28)

1. Walker JN, Ramracheya R, Zhang Q, Johnson PR, Braun M, Rorsman P. Regulation of glucagon secretion by glucose: paracrine, intrinsic or both? Diabetes Obesity Metabol 2011; 13 Suppl 1:95-105; http://dx.doi.org/10.1111/j.1463-1326.2011.01450.x
2. Lee YS, Jun HS. Anti-diabetic actions of glucagon-like peptide-1 on pancreatic β-cells. Metab 2014; 63:9-19; http://dx.doi.org/10.1016/j.metabol.2013.09.010
3. Cho YM, Wideman RD, Kieffer TJ. Clinical application of glucagon-like Peptide 1 receptor agonists for the treatment of type 2 diabetes mellitus. Endocrinol Metab 2013; 28:262-74; http://dx.doi.org/10.3803/EnM.2013.28.4.262
4. Drucker DJ. Incretin action in the pancreas: potential promise, possible perils, and pathological pitfalls. Diabetes 2013; 62:3316-23; PMID:23818527; http://dx.doi.org/10.2337/db13-0822
5. Butler AE, Campbell-Thompson M, Gurlo T, Dawson DW, Atkinson M, Butler PC. Marked expansion of exocrine and endocrine pancreas with incretin therapy in humans with increased exocrine pancreas dysplasia and the potential for glucagon-producing neuroendocrine tumors. Diabetes 2013; 62:2595-604; PMID:23524641; http://dx.doi.org/10.2337/db12-1686
6. Parkes DG, Mace KF, Trautmann ME. Discovery and development of exenatide: the first antidiabetic agent to leverage the multiple benefits of the incretin hormone, GLP-1. Exp Opin Drug Discov 2013; 8:219-44; http://dx.doi.org/10.1517/17460441.2013.741580
7. Nyborg NC, Molck AM, Madsen LW, Knudsen LB. The human GLP-1 analog liraglutide and the pancreas: evidence for the absence of structural pancreatic changes in three species. Diabetes 2012; 61:1243-9; PMID:22338093; http://dx.doi.org/10.2337/db11-0936
8. Engel SS, Williams-Herman DE, Golm GT, Clay RJ, Machotka SV, Kaufman KD, Goldstein BJ. Sitagliptin: review of preclinical and clinical data regarding incidence of pancreatitis. Int J Clin Practice 2010; 64:984-90; http://dx.doi.org/10.1111/j.1742-1241.2010.02382.x
9. Sato K, Nakamura A, Shirakawa J, Muraoka T, Togashi Y, Shinoda K, Orime K, Kubota N, Kadowaki T, Terauchi Y. Impact of the dipeptidyl peptidase-4 inhibitor vildagliptin on glucose tolerance and β-cell function and mass in insulin receptor substrate-2-knockout mice fed a high-fat diet. Endocrinol 2012; 153:1093-102; http://dx.doi.org/10.1210/en.2011-1712
10. Busch SJ, Hoffmann P, Sahota P, Johnson R, Kothny W, Meyer F, Foley JE. Studies in rodents with the dipeptidyl peptidase-4 inhibitor vildagliptin to evaluate possible drug-induced pancreatic histological changes that are predictive of pancreatitis and cancer development in man. Diabetes Obesity Metab 2013; 15:72-6; http://dx.doi.org/10.1111/j.1463-1326.2012.01678.x
11. Quan W, Lee MS. Role of autophagy in the control of body metabolism. Endocrinol Metab 2013; 28:6-11; http://dx.doi.org/10.3803/EnM.2013.28.1.6
12. Jung HS, Chung KW, Won Kim J, Kim J, Komatsu M, Tanaka K, Nguyen YH, Kang TM, Yoon KH, Kim JW, et al. Loss of autophagy diminishes pancreatic b cell mass and function with resultant hyperglycemia. Cell Metab 2008; 8:318-24; PMID:18840362; http://dx.doi.org/10.1016/j.cmet.2008.08.013
13. Ebato C, Uchida T, Arakawa M, Komatsu M, Ueno T, Komiya K, Azuma K, Hirose T, Tanaka K, Kominami E, et al. Autophagy is important in islet homeostasis and compensatory increase of b cell mass in response to high-fat diet. Cell Metab 2008; 8:325-32; PMID:18840363; http://dx.doi.org/10.1016/j.cmet.2008.08.009
14. Wu JJ, Quijano C, Chen E, Liu H, Cao L, Fergusson MM, Rovira II, Gutkind S, Daniels MP, Komatsu M, et al. Mitochondrial dysfunction and oxidative stress mediate the physiological impairment induced by the disruption of autophagy. Aging 2009; 1:425-37; PMID:20157526
15. Kim MJ, Choi OK, Chae KS, Kim MK, Kim JH, Komatsu M, Tanaka K, Lee H, Chung SS, Kwak SH, et al. Mitochondrial Complexes I and II Are More Susceptible to Autophagy Deficiency in Mouse β-cells. Endocrinol Metab 2015; 30:65-70; http://dx.doi.org/10.3803/EnM.2015.30.1.65
16. Masini M, Bugliani M, Lupi R, del Guerra S, Boggi U, Filipponi F, Marselli L, Masiello P, Marchetti P. Autophagy in human type 2 diabetes pancreatic b cells. Diabetologia 2009; 52:1083-6; PMID:19367387; http://dx.doi.org/10.1007/s00125-009-1347-2
17. Abe H, Uchida T, Hara A, Mizukami H, Komiya K, Koike M, Shigihara N, Toyofuku Y, Ogihara T, Uchiyama Y, et al. Exendin-4 Improves β-cell Function in Autophagy-Deficient β-cells. Endocrinol 2013; 154:4512-24; http://dx.doi.org/10.1210/en.2013-1578
18. Seino S. Cell signalling in insulin secretion: the molecular targets of ATP, cAMP and sulfonylurea. Diabetologia 2012; 55:2096-108; PMID:22555472
19. Kawamori D, Kurpad AJ, Hu J, Liew CW, Shih JL, Ford EL, Herrera PL, Polonsky KS, McGuinness OP, Kulkarni RN. Insulin signaling in α cells modulates glucagon secretion in vivo. Cell Metab 2009; 9:350-61; PMID:19356716; http://dx.doi.org/10.1016/j.cmet.2009.02.007
20. Ding WG, Renstrom E, Rorsman P, Buschard K, Gromada J. Glucagon-like peptide I and glucosedependent insulinotropic polypeptide stimulate Ca2C-induced secretion in rat α-cells by a protein kinase A-mediated mechanism. Diabetes 1997; 46:792-800; PMID:9133546; http://dx.doi.org/10.2337/diab.46.5.792
21. Rajan S, Torres J, Thompson MS, Philipson LH. SUMO downregulates GLP-1-stimulated cAMP generation and insulin secretion. Am J Physiol Endocrinol Metab 2012; 302:E714-23; PMID:22234371; http://dx.doi.org/10.1152/ajpendo.00486.2011
22. Delmeire D, Flamez D, Hinke SA, Cali JJ, Pipeleers D, Schuit F. Type VIII adenylyl cyclase in rat β cells: coincidence signal detector/generator for glucose and GLP-1. Diabetologia 2003; 46:1383-93; PMID:13680124; http://dx.doi.org/10.1007/s00125-003-1203-8
23. Brouwers B, de Faudeur G, Osipovich AB, Goyvaerts L, Lemaire K, Boesmans L, Cauwelier EJ, Granvik M, Pruniau VP, Van Lommel L, et al. Impaired islet function in commonly used transgenic mouse lines due to human growth hormone minigene expression. Cell Metab 2014; 20:979-90; PMID:25470546; http://dx.doi.org/10.1016/j.cmet.2014.11.004
24. Wicksteed B, Brissova M, Yan W, Opland DM, Plank JL, Reinert RB, Dickson LM, Tamarina NA, Philipson LH, Shostak A, et al. Conditional gene targeting in mouse pancreatic ss-Cells: analysis of ectopic Cre transgene expression in the brain. Diabetes 2010; 59:3090-8; PMID:20802254; http://dx.doi.org/10.2337/db10-0624
25. Elliott AD, Ustione A, Piston DW. Somatostatin and insulinmediate glucose-inhibited glucagon secretion in the pancreatic α-cell by lowering cAMP. Am J Physiol Endocrinol Metab 2015; 308:E130-43; PMID:25406263; http://dx.doi.org/10.1152/ajpendo.00344.2014
26. Komatsu M, Waguri S, Ueno T, Iwata J, Murata S, Tanida I, Ezaki J, Mizushima N, Ohsumi Y, Uchiyama Y, et al. Impairment of starvation-induced and constitutive autophagy in Atg7-deficient mice. J Cell Biol 2005; 169:425-34; PMID:15866887; http://dx.doi.org/10.1083/jcb.200412022
27. Flock G, Baggio LL, Longuet C, Drucker DJ. Incretin receptors for glucagon-like peptide 1 and glucosedependent insulinotropic polypeptide are essential for the sustained metabolic actions of vildagliptin in mice. Diabetes 2007; 56:3006-13; PMID:17717280; http://dx.doi.org/10.2337/db07-0697
28. Yoon KH, Ko SH, Cho JH, Lee JM, Ahn YB, Song KH, Yoo SJ, Kang MI, Cha BY, Lee KW, et al. Selective β-cell loss and α-cell expansion in patients with type 2 diabetes mellitus in Korea. J Clin Endocrinol Metab 2003; 88:2300-8; PMID:12727989; http://dx.doi.org/10.1210/jc.2002-020735